Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026

-- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions --

-- Study in living human heart tissue indicate sotagliflozin acutely and directly reduces myocardial work in hypertrophic cardiomyopathy (HCM) --

-- Findings add mechanistic insight into sotagliflozin's dual SGLT1/SGLT2 inhibition ahead of SONATA-HCM topline results in Q1 2027 --

THE WOODLANDS, Texas, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today announced new data highlighting the cardiovascular effects of its dual SGLT1/2 inhibitor, sotagliflozin, which were shared in two poster presentations at the American Heart Association (AHA) Scientific Sessions 2026. The investigator-initiated studies were sponsored by Lexicon and conducted by investigators at the Ichan School of Medicine at Mount Sinai and Penn Cardiovascular Institute.

In the first presentation, "Zafar et al. Effects of Sotagliflozin and Empagliflozin on Thrombus Formation in Healthy Volunteers: A Randomized Crossover Trial", researchers from the Ichan School of Medicine examined whether sotagliflozin reduces the blood's tendency to form clots, which are the leading cause of heart attacks and strokes.

In the 4-week, randomized, open-label crossover study, 15 healthy adults received once-daily sotagliflozin 400 mg and the selective SGLT2 inhibitor empagliflozin 10 mg in random order. Researchers measured clot formation in participants' blood before and after each treatment, using an ex vivo laboratory model in which blood is drawn over a system that mimics a damaged artery and at speeds that replicate arterial and venous blood flow. Sotagliflozin significantly reduced clot formation from baseline under both arterial-like (11.9%; p=0.043) and venous-like (15.6%; p=0.012) conditions. Reductions with empagliflozin did not reach statistical significance.

The second presentation, "Taichman et al. Load-Dependent Effects of Sodium Glucose Co-Transporter Inhibitors on Work in Human Hypertrophic Cardiomyopathy Living Myocardial Slices," examined whether sotagliflozin acts directly on human heart muscle affected by HCM.

Researchers at Penn Cardiovascular Institute used heart tissue removed from patients with HCM during septal myectomy, a surgery to relieve obstruction, along with tissue from non-failing donor hearts. In an ex vivo model using living myocardial slices, myocardial work was studied across a physiologic range of afterloads, or the pressures the heart pumps against. Short-term exposure to sotagliflozin and empagliflozin directly reduced the work performed by the heart muscle. Sotagliflozin showed increased potency versus empagliflozin at higher afterloads, which mimics the HCM condition. The findings indicate that sotagliflozin can act directly on the heart, independent of its effects on the kidneys and metabolism. The findings were simultaneously published in JACC: Basic to Translational Science.

The ongoing Phase 3 SONATA-HCM trial is evaluating sotagliflozin as a potential treatment option for patients with symptomatic obstructive and non-obstructive HCM. Topline results are expected in the first quarter of 2027.